The PODO Trial
Trial To Evaluate PF-06730512 In Adults With Primary Focal Segmental Glomerulosclerosis
Brief Description
The purpose of this Phase 2 adaptive study is to evaluate PF-06730512 following multiple intravenous infusions in adult patients with primary FSGS. In addition, the intention is to obtain an early indication of efficacy (how well the drug works at improving Urine Protein to Creatinine Ratio).
Trial Physician / Study Coordinator
Michelle Hladunewich
Email PhoneSite Name
Sunnybrook Health Sciences Centre - Kidney Care Centre at the CNIB
1929 Bayview Avenue, Room 390, Toronto, ON M4G 3E8
Sponsor
Pfizer Inc.
Study Drug
PF-06730512
Estimated enrollment
44
Estimated end date
May, 2023
The PODO Trial
Trial To Evaluate PF-06730512 In Adults With Primary Focal Segmental Glomerulosclerosis
Brief Description
The purpose of this Phase 2 adaptive study is to evaluate PF-06730512 following multiple intravenous infusions in adult patients with primary FSGS. In addition, the intention is to obtain an early indication of efficacy (how well the drug works at improving Urine Protein to Creatinine Ratio).
Trial is for people with
Primary focal segmental glomerulosclerosis (FSGS)
Study Goal
To evaluate the safety, tolerability, and possibily efficacy of PF-06730512 in patients with FSGS.
What is involved for the Patient?
Patients will participate for 13 weeks, receiving an intravenous infusion of the study drug weekly.
About the drug or intervention
PF-06730512 works as an antagonist, meaning it possibly reduces the biologic activity that is associated with FSGS.